A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

Change From Baseline in Body Weight

Change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and absolute change from baseline was to be calculated.

Time frame: Baseline, Week 32

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Percentage of participants who achieved at least 5% reduction in body weight from baseline to Week 32.

Time frame: Baseline, Week 32

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Percentage of participants who achieved at least 10% reduction in body weight from baseline to Week 32.

Time frame: Baseline, Week 32

Change From Baseline in Hemoglobin A1c (HbA1c)

Change from baseline in hemoglobin A1c (HbA1c) at Week 32. HbA1c was intended to be measured as a percentage and reflects average blood glucose levels over approximately 3 months.

Time frame: Baseline, Week 32

Pharmacokinetics (PK): Average Concentration of LY3549492

Average plasma concentration of LY3549492. Pharmacokinetic samples were intended to be collected at multiple timepoints, including pre-dose and post-dose intervals, to evaluate the pharmacokinetic profile of LY3549492 over time.

Time frame: Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).